Source: PE Hub Network

VistaPharm: Vertice Pharma closes VistaPharm buy

Vertice Pharma said Tuesday it closed its previously announced acquisition of VistaPharm. Financial terms weren't announced. Warburg Pincus is investing up to $300 million.

Read full article »
VistaPharm's Competitors | VistaPharm's News | VistaPharm's Financials
Stay up-to-date with the latest news on VistaPharm
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
CEO Avatar

Chairman & CEO

John Schutte

CEO Approval Rating

85/100

Read more
Stay up-to-date with the latest news on VistaPharm